Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.
This activity is supported by educational grants from AstraZeneca, Eisai, Inc., Genomic Health, Lilly, Novartis Pharmaceuticals Corporation, Pfizer, and Syndax Pharmaceuticals, Inc.
For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
Release Date: September 28, 2018
Expiration Date: September 28, 2019
Media: Internet - based
Community Practice Connections™: 17th Annual International Congress on the Future of Breast Cancer® features a summary of clinical evidence guiding best practices in the treatment of patients with early-stage and advanced/metastatic breast cancer. The volume of emerging data and new drug approvals is exploding in breast cancer, creating new challenges for the clinician with regard to understanding how this information impacts treatment strategies for the various breast cancer subtypes.
This educational activity is designed to update you on the latest data that have changed practice, or have the potential to change practice, for hormone receptor‒positive, HER2-positive, and triple-negative breast cancers. In addition, this activity will explore the evolving utility of gene expression assays for guiding treatment decision-making. Didactic summaries are accompanied by short video interviews with internationally recognized experts in the management of breast cancer. The video commentaries address decision points, challenges, and questions that you commonly face in community practice, and provide expert perspectives on the implications of recent data for optimizing outcomes for your patients with breast cancer.
Instructions for This Activity and Receiving Credit
This educational activity is directed toward medical, surgical, and radiation oncologists involved in the treatment of patients with breast cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of breast cancer may also participate.
At the conclusion of this activity, you should be better prepared to:
Joyce O'Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor Charles A. Sammons Cancer Center
Co-Chair, Breast Cancer Research Program
The US Oncology Network
Disclosure:Consultant: Novartis, AstraZeneca, Celgene, Lilly, Merck, Pfizer, Seattle Genetics
Sara A. Hurvitz, MD
Associate Professor of Medicine, Division of Hematology/Oncology
Director, Breast Cancer Clinical Research Program
Co-Director, Santa Monica–UCLA Outpatient Hematology/Oncology Practice
David Geffen School of Medicine at UCLA
Santa Monica, CA
Disclosure: Grant/Research Support: Amgen, Bayer, Boehringer Ingelheim, Genentech, GlaxoSmithKline, Pfizer, Roche, Biomarin, Merrimack, OBI Pharma, PUMA, Dignitana, Medivation, Lilly, Novartis; Other: Travel for Lilly, Novartis, OBI
Ian Krop, MD, PhD
Chief, Breast Medical Oncology, Susan F. Smith Center for Women's Cancers
Clinical Research Director, Breast Oncology Center
Associate Professor of Medicine
Harvard Medical School
Disclosure: Grant/ Research Support: Genentech/Roche; Consultant: Daiichi Sankyo; Other: Genentech/Roche (Scientific Advisory Board) and spouse employment at AMAG Pharmaceutical
Ingrid A. Mayer, MD, MSCI
Ingram Professor of Cancer Research
Professor of Medicine
Leader, VICC Breast Cancer Research Program
Co-Principal Investigator, VICC Breast Cancer SPORE
Division of Hematology/ Oncology
Vanderbilt University Medical Center/Vanderbilt-Ingram Cancer Center
Disclosure: Grant/Research Support: Novartis, Pfizer; Other: Novartis, Genentech, AstraZeneca (Scientific Advisory Board)
The staff of Physicians' Education Resource®, LLC, (PER®) have no relevant financial relationships with commercial interests to disclose.
As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.
Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.
This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.
Dec 31, 2018
Medical Crossfire®: Defining New Roles for the Application of PARP Inhibition Strategies in Multiple Tumor Types
Dec 31, 2018
Dec 31, 2018